Cancer market commentary: 3 highlights from ESMO (Part 1)Commentary on key cancer data from ESMO by Stephanie Hawthorne Share XCancer market commentary: 3 highlights from ESMO (Part 1)https://pharmaphorum.com/esmo-2016/cancer-market-commentary-3-highlights-esmo-conference-part-1/
Medivation in merger talks with Sanofi and othersSources say Pfizer and Celgene are also interested. Share XMedivation in merger talks with Sanofi and othershttps://pharmaphorum.com/news/medivation-takeover-talks-sanofi-others/
Possible new breast cancer use for AZ’s FaslodexAstraZeneca has announced results from a phase 3 trial of its breast cancer drug candidate Faslodex (fulvestrant). The drug Share XPossible new breast cancer use for AZ’s Faslodexhttps://pharmaphorum.com/news/possible-new-breast-cancer-use-for-azs-faslodex-after-phase-iii-success/